

DOCKET NO.: CHIR-0157

- 2 -

PATENT

REPLY FILED UNDER EXPEDITED  
PROCEDURE PURSUANT TO  
37 C.F.R. § 1.116

*F1*  
45. (Four times amended) A purified polypeptide comprising at least ten contiguous amino acids of SEQ ID NO:5, wherein said polypeptide includes at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, and six contiguous asparagine residues, which polypeptide is immunologically identifiable by an antibody which reacts specifically with *Helicobacter pylori* CAI antigen.

*F2*  
54. (Four times amended) An immunogenic composition comprising an immunologically effective amount of a recombinant polypeptide, which recombinant polypeptide: (i) comprises at least ten contiguous amino acids of SEQ ID NO:5, wherein said polypeptide includes at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, and six contiguous asparagine residues, and (ii) is immunologically identifiable by an antibody which reacts specifically with *Helicobacter pylori* CAI antigen.

*F3*  
56. (Four times amended) The immunogenic composition of claim 54 wherein said polypeptide comprises at least fifteen contiguous amino acids of SEQ ID NO:5.

57. (Four times amended) The immunogenic composition of claim 54 further comprising an immunologically effective amount of a second polypeptide, which second polypeptide: (i) comprises at least ten contiguous amino acids of *Helicobacter pylori* heat shock protein, and (ii) is immunologically identifiable by an antibody which reacts specifically with *Helicobacter pylori* heat shock protein.

*F4*  
59. (Four times amended) The immunogenic composition of claim 57 wherein said second polypeptide comprises at least fifteen contiguous amino acids of *Helicobacter pylori* heat shock protein.

*F5*  
62. (Four times amended) A method of preparing an immunogenic composition comprising bringing into association:

- (1) an immunologically effective amount of a purified polypeptide, which polypeptide: (i) comprises at least ten contiguous amino acids of SEQ ID NO:5, wherein said polypeptide includes at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, and six contiguous

REPLY FILED UNDER EXPEDITED  
PROCEDURE PURSUANT TO  
37 C.F.R. § 1.116

asparagine residues, and (ii) is immunologically identifiable by an antibody which reacts specifically with *Helicobacter pylori* CAI antigen, and  
(2) a pharmaceutically acceptable carrier.

F5  
63. (Four times amended) The method of claim 62 or 78 further comprising adding an immunologically effective amount of a second polypeptide, which second polypeptide: (i) comprises at least ten contiguous amino acids of *Helicobacter pylori* heat shock protein, and (ii) is immunologically identifiable by an antibody which reacts specifically with *Helicobacter pylori* heat shock protein.

Sub F6  
70. (Three times amended) The immunogenic composition of claim 54, further comprising an immunologically effective amount of a second polypeptide, wherein said second polypeptide: (i) comprises at least ten contiguous amino acids of *Helicobacter pylori* cytotoxin (CT) protein, and (ii) is immunologically identifiable by an antibody which reacts specifically with *Helicobacter pylori* cytotoxin.

Sub F7  
75. (Twice amended) A recombinant polypeptide comprising at least ten contiguous amino acids of SEQ ID NO:5, wherein said polypeptide includes at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, and six contiguous asparagine residues, which recombinant polypeptide is immunologically identifiable by an antibody which reacts specifically with *Helicobacter pylori* CAI antigen.

Sub F8  
78. (Twice amended) A method of preparing an immunogenic composition comprising bringing into association:

(1) an immunologically effective amount of a recombinant polypeptide, which recombinant polypeptide: (i) comprises at least ten contiguous amino acids of SEQ ID NO:5, wherein said polypeptide includes at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, and six contiguous asparagine residues, and (ii) is immunologically identifiable by an antibody which reacts specifically with *Helicobacter pylori* CAI antigen, and  
(2) a pharmaceutically acceptable carrier.

REPLY FILED UNDER EXPEDITED  
PROCEDURE PURSUANT TO  
37 C.F.R. § 1.116

*E9*  
80. (Twice amended) The immunogenic composition of claim 70 wherein said second polypeptide comprises at least fifteen contiguous amino acids of *Helicobacter pylori* CT protein.

*E10*  
81. (Amended) An isolated immunogenic polypeptide comprising at least five contiguous amino acids from SEQ ID NO:5, wherein said polypeptide is immunologically identifiable by an antibody which reacts specifically with *Helicobacter pylori* CAI antigen.

Please cancel claims 92, 94-120, 129, and 131-138 without prejudice to the prosecution of the subject matter contained therein at a later date.